- InflaRx's primary clinical trial encounters setback, significantly impacting stock prices.
- Analyst predictions suggest potential long-term value in InflaRx shares.
- Company pivots towards other therapeutic ventures while maintaining COVID-19 treatment availability.
InflaRx (IFRX) experienced a dramatic stock decline of over 50% following the decision to halt trials of its lead drug, vilobelimab, aimed at treating pyoderma gangrenosum, due to underwhelming interim results. In response, InflaRx is shifting focus to its small molecule therapy, INF904, while also adopting cost-saving strategies. Despite this setback, vilobelimab remains accessible for the treatment of COVID-19.
Wall Street Analysts Forecast
According to forecasts from seven analysts over the next year, InflaRx NV's (IFRX) average target price is positioned at $8.84. This includes a high projection of $12.97 and a low of $4.99, suggesting a potential upside of 385.69% from the current market price of $1.82. For more detailed estimation data, visit the InflaRx NV (IFRX, Financial) Forecast page.
The consensus from eight brokerage firms rates InflaRx NV (IFRX) at an average of 1.6, indicating an "Outperform" recommendation. This rating is on a scale where 1 represents Strong Buy and 5 indicates Sell.
